This is a Study to Determine the Antidepressant Effects of AZD6765

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Antidepressive Agents

Criteria

Inclusion Criteria:

• Patients with a diagnosis of Major Depressive Disorder, currently depressed without psychotic features

• Females must be of non-childbearing potential.

Exclusion Criteria:

• Treatment with Clozapine or ECT within 3 months prior to study

• Current or past history of psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV